The main purpose of this study is to evaluate the effects of itraconazole or etravirine on the single-dose pharmacokinetics (PK) of JNJ 64417184 in healthy adult participants.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
32
JNJ 64417184 tablets will be administered orally.
Itraconazole capsules will be administered orally
etravirine tables will be administered orally.
SGS Clinical Pharmacology Unit (located in ZNA Stuivenberg)
Antwerp, Belgium
Maximum Observed Plasma Analyte concentration (Cmax) of JNJ 64417184
Cmax is defined as maximum observed plasma analyte.
Time frame: Predose up to 144 hours post dose
Area Under the Concentration-time Curve from Time Zero to the Last Measurable Concentration (AUC [0-last]) of JNJ 64417184
AUC (0-last) is defined as the area under the plasma analyte concentration- time curve (AUC) from time 0 to the time of the last measurable (non-below qualification limit) concentration.
Time frame: Predose up to 144 hours post dose
Area Under the Concentration-time Curve from Time Zero to Infinity (AUC [0-infinity]) of JNJ 64417184
AUC (0-infinity) is defined as AUC from time 0 to infinite time, calculated as the sum of AUC(0-last) and C(last)/ lambda(z), wherein C(last) is the last observed quantifiable concentration; extrapolations of more than 20 percent (%) of the total AUC.
Time frame: Predose up to 144 hours post dose
Number of Participants with Adverse Events (AE) as a Measure of Safety and Tolerability
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Time frame: Up to 54 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.